Co Diagnostics Financials
| CODX Stock | USD 1.01 0.05 4.72% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.9 | 10.8117 |
|
|
Investors should never underestimate Co Diagnostics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Co Diagnostics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Co Diagnostics.
Net Income |
|
CODX | Select Account or Indicator |
Understanding current and past Co Diagnostics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Co Diagnostics' financial statements are interrelated, with each one affecting the others. For example, an increase in Co Diagnostics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Co Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Co Diagnostics. Check Co Diagnostics' Beneish M Score to see the likelihood of Co Diagnostics' management manipulating its earnings.
Co Diagnostics Stock Summary
Co Diagnostics competes with Heart Test, NanoVibronix, Rapid Micro, Biomerica, and Bluejay Diagnostics. Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules in the United States and internationally. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Co Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US1897631057 |
| CUSIP | 189763105 |
| Location | Utah; U.S.A |
| Business Address | 2401 South Foothill |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.codiagnostics.com |
| Phone | (801) 438 1036 |
| Currency | USD - US Dollar |
Co Diagnostics Key Financial Ratios
| Return On Equity | -0.51 | ||||
| Operating Margin | (15.96) % | ||||
| Price To Sales | 4.41 X | ||||
| Revenue | 6.81 M | ||||
| Gross Profit | 28.74 M |
Co Diagnostics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 2.2M | 71.2M | 160.0M | 123.1M | 95.3M | 50.6M | |
| Net Tangible Assets | 1.7M | 66.7M | 92.6M | 87.8M | 100.9M | 106.0M | |
| Retained Earnings | (25.0M) | 17.5M | 54.2M | 39.9M | 4.6M | 5.5M | |
| Accounts Payable | 6.0K | 598.3K | 607.5K | 952.3K | 1.5M | 1.6M | |
| Cash | 893.1K | 43.0M | 88.6M | 23.0M | 14.9M | 19.4M | |
| Capital Surpluse | 26.7M | 49.2M | 80.3M | 88.5M | 101.7M | 106.8M | |
| Total Liab | 478.1K | 4.5M | 25.6M | 8.6M | 9.3M | 6.4M | |
| Total Current Assets | 1.6M | 68.4M | 115.1M | 92.7M | 62.1M | 38.2M | |
| Common Stock | 17.3K | 28.6K | 33.8K | 34.8K | 36.1K | 22.9K | |
| Other Current Liab | 320.8K | 3.4M | 9.6M | 1.1M | 1.6M | 2.2M | |
| Net Debt | (893.1K) | (43.0M) | (88.6M) | (22.6M) | (11.9M) | (12.5M) | |
| Net Receivables | 131.4K | 12.1M | 20.9M | 5.4M | 330.9K | 314.3K | |
| Other Current Assets | 362.6K | 916.3K | 2.3M | 761.2K | 1.6M | 889.4K | |
| Other Liab | 150K | 30K | 13.0M | 4.6M | 5.3M | 3.3M | |
| Inventory | 197.2K | 8.0M | 2.0M | 5.3M | 1.7M | 2.7M | |
| Net Invested Capital | 1.7M | 66.7M | 134.5M | 114.5M | 86.0M | 64.1M | |
| Net Working Capital | 1.3M | 63.8M | 102.5M | 88.9M | 56.4M | 49.6M |
Co Diagnostics Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 106.4K | 175.0 | 473.5K | 14.9M | 17.1M | 18.0M | |
| Total Revenue | 215.0K | 74.6M | 97.9M | 34.2M | 6.8M | 6.5M | |
| Gross Profit | 102.5K | 58.0M | 86.3M | 28.7M | 2.6M | 2.5M | |
| Operating Income | (5.9M) | 41.7M | 46.1M | (11.6M) | (42.7M) | (40.6M) | |
| Ebit | (5.9M) | 41.7M | 46.1M | (11.6M) | (42.7M) | (40.6M) | |
| Research Development | 1.4M | 3.2M | 15.0M | 17.4M | 23.0M | 24.1M | |
| Cost Of Revenue | 112.4K | 16.6M | 11.6M | 5.5M | 4.2M | 4.2M | |
| Income Before Tax | (6.2M) | 42.6M | 45.6M | (18.8M) | (38.1M) | (36.2M) | |
| Net Income | (6.1M) | 42.5M | 36.7M | (14.2M) | (35.3M) | (33.6M) | |
| Income Tax Expense | (126.4K) | 90.5K | 9.0M | (4.6M) | (2.8M) | (2.6M) | |
| Interest Income | 36.7K | 97.2K | 45.6K | 704.0K | 1.0M | 1.1M | |
| Ebitda | (6.0M) | 41.8M | 46.4M | (10.3M) | (41.5M) | (39.4M) | |
| Net Interest Income | (69.8K) | 97.2K | 45.6K | 704.0K | 1.0M | 1.1M |
Co Diagnostics Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Co Diagnostics. It measures of how well CODX is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Co Diagnostics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money CODX had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Co Diagnostics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (179.0K) | (7.9M) | 5.7M | (3.5M) | 413.1K | 433.8K | |
| Investments | (322K) | (5.8M) | 3.6M | (56.7M) | (47.5M) | (45.2M) | |
| Change In Cash | (57.1K) | 42.1M | 45.6M | (65.6M) | (8.1M) | (7.7M) | |
| Depreciation | 65.9K | 138.6K | 335.4K | 1.3M | 1.2M | 1.3M | |
| Capital Expenditures | 113.2K | 774.4K | 669.5K | 1.4M | 1.4M | 1.4M | |
| Net Income | (6.2M) | 42.5M | 36.7M | (14.2M) | (35.3M) | (33.6M) | |
| End Period Cash Flow | 893.1K | 43.0M | 88.6M | 23.0M | 14.9M | 19.4M | |
| Change To Netincome | 1.3M | 2.4M | 7.0M | 21.0M | 24.2M | 25.4M | |
| Free Cash Flow | (5.6M) | 27.4M | 40.4M | 5.1M | (23.4M) | (22.3M) | |
| Other Non Cash Items | 91.4K | 176.6K | 544.5K | 10.4M | 460.3K | 437.3K | |
| Change Receivables | (121.5K) | (13.0M) | (8.7M) | 15.0M | 17.2M | 18.1M |
CODX Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Co Diagnostics's current stock value. Our valuation model uses many indicators to compare Co Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Co Diagnostics competition to find correlations between indicators driving Co Diagnostics's intrinsic value. More Info.Co Diagnostics is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Co Diagnostics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Co Diagnostics' earnings, one of the primary drivers of an investment's value.Co Diagnostics Systematic Risk
Co Diagnostics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Co Diagnostics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Co Diagnostics correlated with the market. If Beta is less than 0 Co Diagnostics generally moves in the opposite direction as compared to the market. If Co Diagnostics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Co Diagnostics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Co Diagnostics is generally in the same direction as the market. If Beta > 1 Co Diagnostics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Co Diagnostics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Co Diagnostics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Co Diagnostics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Co Diagnostics November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Co Diagnostics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Co Diagnostics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Co Diagnostics based on widely used predictive technical indicators. In general, we focus on analyzing CODX Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Co Diagnostics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.19) | |||
| Maximum Drawdown | 22.62 | |||
| Value At Risk | (6.20) | |||
| Potential Upside | 5.6 |
Additional Tools for CODX Stock Analysis
When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.